422 related articles for article (PubMed ID: 33290737)
1. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial.
Halton J; Brandão LR; Luciani M; Bomgaars L; Chalmers E; Mitchell LG; Nurmeev I; Sharathkumar A; Svirin P; Gorbatikov K; Tartakovsky I; Simetzberger M; Huang F; Sun Z; Kreuzer J; Gropper S; Reilly P; Brueckmann M; Albisetti M;
Lancet Haematol; 2021 Jan; 8(1):e22-e33. PubMed ID: 33290737
[TBL] [Abstract][Full Text] [Related]
2. Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability.
Halton JML; Albisetti M; Biss B; Bomgaars L; Brueckmann M; Gropper S; Harper R; Huang F; Luciani M; Maas H; Tartakovsky I; Mitchell LG
J Thromb Haemost; 2017 Nov; 15(11):2147-2157. PubMed ID: 28921890
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.
Male C; Lensing AWA; Palumbo JS; Kumar R; Nurmeev I; Hege K; Bonnet D; Connor P; Hooimeijer HL; Torres M; Chan AKC; Kenet G; Holzhauer S; Santamaría A; Amedro P; Chalmers E; Simioni P; Bhat RV; Yee DL; Lvova O; Beyer-Westendorf J; Biss TT; Martinelli I; Saracco P; Peters M; Kállay K; Gauger CA; Massicotte MP; Young G; Pap AF; Majumder M; Smith WT; Heubach JF; Berkowitz SD; Thelen K; Kubitza D; Crowther M; Prins MH; Monagle P;
Lancet Haematol; 2020 Jan; 7(1):e18-e27. PubMed ID: 31699660
[TBL] [Abstract][Full Text] [Related]
4. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.
Monagle P; Lensing AWA; Thelen K; Martinelli I; Male C; Santamaría A; Samochatova E; Kumar R; Holzhauer S; Saracco P; Simioni P; Robertson J; Grangl G; Halton J; Connor P; Young G; Molinari AC; Nowak-Göttl U; Kenet G; Kapsa S; Willmann S; Pap AF; Becka M; Twomey T; Beyer-Westendorf J; Prins MH; Kubitza D;
Lancet Haematol; 2019 Oct; 6(10):e500-e509. PubMed ID: 31420317
[TBL] [Abstract][Full Text] [Related]
5. Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism.
Paik J
Paediatr Drugs; 2022 Jul; 24(4):423-431. PubMed ID: 35699915
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism.
Halton JML; Picard AC; Harper R; Huang F; Brueckmann M; Gropper S; Maas H; Tartakovsky I; Nurmeev I; Mitchell LG; Brandão LR; Chalmers E; Albisetti M
Thromb Haemost; 2017 Nov; 117(11):2168-2175. PubMed ID: 29202215
[TBL] [Abstract][Full Text] [Related]
7. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
[TBL] [Abstract][Full Text] [Related]
8. Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial.
O'Brien SH; Rodriguez V; Lew G; Newburger JW; Schultz CL; Orgel E; Derr K; Ranalli MA; Esbenshade AJ; Hochberg J; Kang HJ; Dinikina Y; Mills D; Donovan M; Dyme JL; Favatella NA; Mitchell LG;
Lancet Haematol; 2024 Jan; 11(1):e27-e37. PubMed ID: 37980924
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
Eriksson BI; Dahl OE; Rosencher N; Kurth AA; van Dijk CN; Frostick SP; Prins MH; Hettiarachchi R; Hantel S; Schnee J; Büller HR;
Lancet; 2007 Sep; 370(9591):949-56. PubMed ID: 17869635
[TBL] [Abstract][Full Text] [Related]
10. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.
Brandão LR; Albisetti M; Halton J; Bomgaars L; Chalmers E; Mitchell LG; Nurmeev I; Svirin P; Kuhn T; Zapletal O; Tartakovsky I; Simetzberger M; Huang F; Sun Z; Kreuzer J; Gropper S; Brueckmann M; Luciani M;
Blood; 2020 Feb; 135(7):491-504. PubMed ID: 31805182
[TBL] [Abstract][Full Text] [Related]
11. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.
Devereaux PJ; Duceppe E; Guyatt G; Tandon V; Rodseth R; Biccard BM; Xavier D; Szczeklik W; Meyhoff CS; Vincent J; Franzosi MG; Srinathan SK; Erb J; Magloire P; Neary J; Rao M; Rahate PV; Chaudhry NK; Mayosi B; de Nadal M; Iglesias PP; Berwanger O; Villar JC; Botto F; Eikelboom JW; Sessler DI; Kearon C; Pettit S; Sharma M; Connolly SJ; Bangdiwala SI; Rao-Melacini P; Hoeft A; Yusuf S;
Lancet; 2018 Jun; 391(10137):2325-2334. PubMed ID: 29900874
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
[TBL] [Abstract][Full Text] [Related]
13. Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial.
Klok FA; Toenges G; Mavromanoli AC; Barco S; Ageno W; Bouvaist H; Brodmann M; Cuccia C; Couturaud F; Dellas C; Dimopoulos K; Duerschmied D; Empen K; Faggiano P; Ferrari E; Galiè N; Galvani M; Ghuysen A; Giannakoulas G; Huisman MV; Jiménez D; Kozak M; Lang IM; Lankeit M; Meneveau N; Münzel T; Palazzini M; Petris AO; Piovaccari G; Salvi A; Schellong S; Schmidt KH; Verschuren F; Schmidtmann I; Meyer G; Konstantinides SV;
Lancet Haematol; 2021 Sep; 8(9):e627-e636. PubMed ID: 34363769
[TBL] [Abstract][Full Text] [Related]
14. Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
Schulman S; Kearon C; Kakkar AK; Mismetti P; Schellong S; Eriksson H; Baanstra D; Schnee J; Goldhaber SZ;
N Engl J Med; 2009 Dec; 361(24):2342-52. PubMed ID: 19966341
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. An open-label phase IIa study.
Halton JM; Lehr T; Cronin L; Lobmeyer MT; Haertter S; Belletrutti M; Mitchell LG
Thromb Haemost; 2016 Aug; 116(3):461-71. PubMed ID: 27357738
[TBL] [Abstract][Full Text] [Related]
16. Design and rationale for the DIVERSITY study: An open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolism.
Albisetti M; Biss B; Bomgaars L; Brandão LR; Brueckmann M; Chalmers E; Gropper S; Harper R; Huang F; Luciani M; Manastirski I; Mitchell LG; Tartakovsky I; Wang B; Halton JML
Res Pract Thromb Haemost; 2018 Apr; 2(2):347-356. PubMed ID: 30046738
[TBL] [Abstract][Full Text] [Related]
17. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P
Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066
[TBL] [Abstract][Full Text] [Related]
18. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Schulman S; Kakkar AK; Goldhaber SZ; Schellong S; Eriksson H; Mismetti P; Christiansen AV; Friedman J; Le Maulf F; Peter N; Kearon C;
Circulation; 2014 Feb; 129(7):764-72. PubMed ID: 24344086
[TBL] [Abstract][Full Text] [Related]
19. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
[TBL] [Abstract][Full Text] [Related]
20. Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
Stepien K; Nowak K; Zalewski J; Pac A; Undas A
Vascul Pharmacol; 2019 Sep; 120():106567. PubMed ID: 31158568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
